WO1984003280A1 - Glycine-8-calcitonine - Google Patents

Glycine-8-calcitonine Download PDF

Info

Publication number
WO1984003280A1
WO1984003280A1 PCT/US1983/000221 US8300221W WO8403280A1 WO 1984003280 A1 WO1984003280 A1 WO 1984003280A1 US 8300221 W US8300221 W US 8300221W WO 8403280 A1 WO8403280 A1 WO 8403280A1
Authority
WO
WIPO (PCT)
Prior art keywords
cycle
boc
resin
gly
peptide
Prior art date
Application number
PCT/US1983/000221
Other languages
English (en)
Inventor
Ronald C Orlowski
Jay K Seyler
Original Assignee
Armour Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armour Pharma filed Critical Armour Pharma
Priority to JP58501114A priority Critical patent/JPS60500055A/ja
Priority to PCT/US1983/000221 priority patent/WO1984003280A1/fr
Publication of WO1984003280A1 publication Critical patent/WO1984003280A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/585—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to calcitonins having biological activity and to peptides which can be converted to biologically active calcitonins and to processes for preparing such peptides and calcitonins.
  • Salmon calcitonin for example, has the following formula:
  • the natural calcitonins include the salmon calcitonins, eel, bovine, porcine and ovine calcitonins and human calcitonins. All of these have valine at position number 8 except human calcitonin which has methonine at position number 8.
  • BHA resin benzhydryl amine resin
  • This resin is derived from a cross-linked polystyrene bead resin manufactured by copolymerization of styre ⁇ ie and divinylbenzene. Resin of this type is known and its preparation is further demonstrated by Pietta et al [Pietta, P.S. and Marshall, G.R. , Chem. Commun. , 650 (1970)].
  • This cross-linked polystyrene BHA resin is available from chemical supply houses. We use the designation
  • the amino acids are added one at a time to the insoluble resin until the total peptide sequence has been built up on the resin.
  • the functional groups of the amino acids are protected by blocking groups.
  • the ⁇ -amino group of .the amino acids is protected by a tertiary butyloxycarbonyl group or an equivalent thereof. This ⁇ -tertiary butyloxycarbonyl group we designate as BOC.
  • benzyl or benzyl derivative group such as 4-methoxybenzyl, 4-methylbenzyl, 3,4-di ⁇ nethylbenzyl, 4-chlorobenzyl, 2,6-dichlorobenzyl, 4-nitrobenzyl, benzhydryl or an equivalent thereof.
  • BZ to represent the benzyl or benzyl derivative group.
  • the hydroxyl function of tyrosine may be unprotected, may be protected by a benzyl or benzyl derivative group as described above, as a BZ group, or may be protected by a benzyloxycarbonyl or a benzyloxycarbonyl derivative such as 2-chlorobenzyloxycarbonyl or 2-bromobenzyloxycarbonyl group or equivalent thereof.
  • W we use the term W to represent either no protective group, a BZ group, a benzyloxycarbonyl group or a benzyloxycarbonyl derivative group.
  • the thiol function of cysteine may be protected by benzyl or benzyl protective groups described above and designated BZ or by an n-alkylthio group such as methylthio, ethylthio, n-propylthio, n-butylthio or equivalents thereof.
  • R 2 to represent an n-alkylthio group or BZ
  • R 1 to represent BZ when R 2 is n-alkylthio and to represent n-alkylthio when R 2 is BZ .
  • R 1 may be another cysteine group and when this is the case R 2 is BZ.
  • the guanidine function of arginine may be protected by a nitro group, a tosyl group or an equivalent thereof.
  • the ⁇ -amino function of lysine may be protected by a benzyloxycarbonyl group or a benzyloxycarbonyl derivative such a 2-chlorobenzyloxycarbonyl, 3, 4-dimethylbenzyloxycarbonyl, or equivalents thereof.
  • We use the character V to represent benzyloxycarbonyl, group or a benzyloxycarbonyl derivative group.
  • the protective groups used on the imidazole nitrogen of histidine are the benzyloxycarbonyl group and benzyloxycarbonyl derivatives such as described above for lysine and are designated as V.
  • the ⁇ - carboxylic acid group of glutamic acid is protected by a benzyl or benzyl derivative group such as described for the protection of the hydroxyl function of serine and threonine.
  • These protective groups are represented by the character BZ.
  • Preferred amino acid reactants for use in each of the 32 cycles of the synthesis are given in the following Table I: benzyl-L-cysteine or BOC-S-3,4-dimethylbenzyl- L-cysteine Bis-BOC-Cystine
  • Table I benzyl-L-cysteine or BOC-S-3,4-dimethylbenzyl- L-cysteine Bis-BOC-Cystine
  • the reaction vessel used in all steps of the resin peptide synthesis may be a glass vessel equipped with inlet ports at the top for addition of materials and a sintered glass disk at the bottom for removal of soluble reaction mixtures and wash solvents by filtration. Filtration may be performed either by vacuum or the use of nitrogen pressure.
  • the contents of the vessel may be agitated by shaking the entire vessel or by mechanical stirrer.
  • the BHA resin is placed in the reaction vessel and suspended in a solvent such as methylene chloride, chloroform, dimethylformamide, benzene or equivalents thereof in proportions of about 3 to 12 ml. of solvent per gram of resin.
  • a solvent such as methylene chloride, chloroform, dimethylformamide, benzene or equivalents thereof in proportions of about 3 to 12 ml. of solvent per gram of resin.
  • BOC-L-proline in an amount of about 1 to 6 equivalents per free amine equivalent of the BHA resin employed.
  • a coupling reagent such as dicyclohexyl carbodiimide (DCC) may be added, or other diimide coupling agents may be used.
  • the diimide coupling agent may be used in the amount of 0.5 to 2.0 equivalents per equivalent of BOC-L-proline used.
  • the BOC-L-proline may be coupled in the absence of a coupling reagent if its active ester derivative, its azide derivative, its symmetrical anhydride derivative, or a suitably chosen mixed anhydride derivative is used.
  • Active ester derivatives that may be employed are 2-nitrophenyl ester, 4-nitrophenyl ester, pentafluorophenyl ester, N-hydroxysuccimide ester or equivalents thereof.
  • the active esters are used in amounts of 1 to 10 equivalents per free amine equivalent of BHA resin.
  • the reaction mixture consisting of the BHA resin, the solvent, the BOC-L-proline, and the coupling reagent or BOC-L-proline active ester is stirred or shaken mechanically until the reaction is complete as indicated by a ninhydrin test [E. Kaiser, et al., Anal. Biochem., 34, 595-8 (1970)] on a test sample.
  • the BOC-L-proline resin may be washed with solvents such as methylene chloride, chloroform, methyl alcohol, benzene, dimethylformamide, or acetic acid.
  • the amount of wash solvent may suitably be 5 to 20 ml. of solvent for each gram of BHA resin used initially.
  • the washing procedure may be used and the remaining free amino groups on the BOC-L-proline resin may be blocked from further reaction by acetylation with an excess of acetylaton reagents.
  • the acetylation procedure may be performed by agitating the BOC-L-proline resin with a solution of the acetylation reagent for a period of 0.5 to 12 hours.
  • Acetylation reagents such as N-acetylimidazole in methylene chloride solution or a mixture of acetic anhydride and triethylamine in chloroform may be used.
  • the acetylaton reagent may be used in the amount of 0.5 to 5.0 equivalents per equivalent of free amine titer of the starting BHA resin.
  • the coupling reaction to produce the BOC-L-proline resin may be described by the following formula:
  • the BOC-L-proline resin produced as above described may be washed with a solvent such as referred to above and deprotected by agitating it with an agent such as a mixture of trifluoroacetic acid (TFA) in a solvent such as methylene chloride, chloroform, benzene or equivalents thereof.
  • TFA trifluoroacetic acid
  • the amount of TFA in the solvent may vary from 10 to 100% of the mixture.
  • the amount of TFA-solvent mixture may vary from 3 to 20 ml. per gram of BHA resin used initially.
  • the reaction time may be from about 10 minutes to 4 hours.
  • the deprotection step is terminated by filtration to remove the TFA-solvent mixture.
  • the residual TFA may be removed from the L-proline resin by washing with 3 to 20 ml.
  • BHA resin per gram of BHA resin of solution of 5 to 30% of triethylamine in a solvent such as methylene chloride, chloroform, benzene or equivalents thereof.
  • a solvent such as methylene chloride, chloroform, benzene or equivalents thereof.
  • Other tertiary or secondary organic amines may be used in place of the triethylamine, such as, trimethylamine, N-ethylpiperidine, diisopropylamine or equivalents thereof.
  • the free amine titer of the L-proline resin may be determined by the Dorman titration procedure (Dorman, L.C., Tetrahedron Letters, 1969, 2319-21). The deprotection reaction may be described by the following formula:
  • the prolyl BHA resin obtained as a result of cycle 32 may be suspended in a coupling solvent, the BOC-O-BZ-L threonine derivative added and the mixture equilibrated in the same manner.
  • the coupling agent, DCC may be added, and after completion of the reaction as indicated by the ninhydrin test, the reaction mixture may be removed from the BOC-O-BZ threonylprolyl BHA resin by filtration.
  • the peptide resin may be washed with solvents.
  • the amounts of reactants and solvents and reaction times may be the same as described in cycle 32.
  • the BOC group may be removed from the peptide resin by the deprotection method described in the cycle 32.
  • the resulting O-BZ-threonylprolyl BHA resin is then ready for cycle 30.
  • the reactions of the cycle 31 may be shown by the following formula:
  • the coupling reaction and also the deprotection reaction may be performed in the same manner as in cycle 31 except that BOC-glycine is used in place of BOC-O-BZ-L-threonine.
  • the reaction through coupling and deprotection may be written:
  • the coupling and deprotection reactions may be as in cycle 31 using the same amino acid reactant, resulting in the following compound:
  • the coupling reaction is performed using an active ester derivative of BOC-L-asparagine.
  • the active ester procedure is used in place of the DCC coupling agent with BOC-asparagine or BOC-glutamine.
  • the reaction may be performed using the active ester derivative of BOC-L-asparagine in the amount of 2 to 10 equivalents per free amine equivalent of BHA resin in dimethylformamide, mixtures of dimethylformamide with benzene, methylene chloride or chloroform or with equivalents thereof in amount of 2 to 20 ml. of solvent per gram of BHA resin used initially.
  • Reaction times range from 1 to 72 hours.
  • the reaction mixture may be removed from the BOC peptide resin by filtration after completion of the reaction as indicated by a ninhydrin test.
  • the active esters derivative employed may be 2-nitrophenyl esters, 4-nitrophenyl esters, pentafluorophenyl, or equivalents thereof. We use AE to designate the active ester portion of the derivative.
  • the coupling reaction may be written:
  • the deprotect ion react ion to remove the BOC group is performed as in cycle 32.
  • the coupling and deprotection reactions may be conducted using the methods and proportions of reactants as in cycle 31, using BOC-BZ-L-threonine in cycle 25, BOC- ⁇ -T-L-arginine in cycle 24, BOC-L-proline in cycle 23, BOC-L-leucine in cycle 22, and BOC-O-BZ-L-threonine in cycle 21.
  • the compound resulting from the completion of cycle 21 may be written:
  • the coupling and deprotection reactions may be performed using the methods and proportions of reactants as in cycle 26 using a BOC-L-glutamine active ester derivative as the amino acid derivative, resulting in the compound:
  • cycle 19 the reactions are performed as in cycle 31 using BOC-L-leucine as the amino acid der ivat ive .
  • the compound resulting from cycle 19 is :
  • cycle 18 we may use as the amino acid der ivative BOC- ⁇ -V-L-lysine . Otherwise , cycle 18 methods may performed as in cycle 31 resulting in the compound :
  • Cycles 17 to 15 may be performed as in cycle 31 except for the use of BOC-N(im)-V-L-histidine in cycle 17, BOC-L-leucine as the reactant in cycle 16 and BOC-L-glutamic acid BZ ester (BZ represents the same groups as it represents for serine and threonine) as the reactant in cycle 15, resulting in the following compound from cycle 15:
  • Cycle 14 may be performed identically to cycle 20 using BOC-L-glutamine-AE as the amino acid derivative.
  • Cycles 13 to 8 may be performed as in cycle 31 except for the use of BOC-O-BZ-L-serine in cycle 13, BOC-L-leucine in cycle 12, BOC- ⁇ -V-L-lysine in cycle 11, BOC-glycine in cycle 10, BOC-L-leucine in cycle 9, and BOC-L-Gylcine cycle 8 resulting in the compound:
  • Cycle 7 may be performed as in cycle 31 except for the use of BOC-S-L-cysteine or for the amino acid derivative.
  • the compounds resulting from cycle 7 are described by the formula:
  • R 2 is an alkylthio or a BZ group.
  • Cycles 6 to 4 may be performed as in cycle 31 except that BOC-O-BZ-L-threonine be used as the amino acid derivative in cycle 6, BOC-BZ-L-serine may be used as the amino acid derivative in cycle 5 and cycle 2, and BOC-L-leucine may be used in cycle 4 as the amino acid derivative.
  • Cycle 3 may be performed identically to cycle 26 using BOC-L-asparagine active ester. The compound resulting from cycle 2 is:
  • This cycle may be performed identically to cycle 7 using BOC-S-R-L-cysteine derivatives.
  • the R group chosen for the cysteine may be the same as used in cycle 7 or different.
  • the derivative chosen for cycle 7 is BOC-S-ethylthio-L-cysteine
  • the derivative in cycle 1 may be BOC-S-4-methoxybenzyl-L-cysteine or if BOC-S-4-methoxybenzyl-L-cysteine was chosen for cycle 7, then this derivative may be used also in cycle 1.
  • the compounds resulting from cycle 1 are illustrated by the formula:
  • R 1 is S-n-alkyl, CYS or Bz and R 2 is S-n-alkyl or Bz, R 1 being alkyl or CYS when R 2 is Bz and R 2 being Bz when R 1 is S-n-alkyl or CYS.
  • Cycle 1 represents the completion of the resin peptide
  • the resin peptide may be removed from the reaction vessel and dried in a vacuum.
  • the weight of the resin peptide may be expected to be from 2.0 to 3.5 times weight of BHA resin used initially in the synthesis.
  • the peptide is cleaved from the resin peptide resulting from cycle 1 by treatment with liquid hydrogen fluoride (HF) .
  • HF liquid hydrogen fluoride
  • the HF cleavage reaction may be performed by treating a mixture of the resin peptide and anisole (0.5 to 5 ml. for each gram of resin peptide) with liquid HF (2 to 20 ml. for each gram of resin peptide) for 0.5 to 20 hours at -20 degrees to +15 degrees centigrade. After the reaction period, the excess HF may be removed by evaporation and the resulting mixture of peptide and resin beads may be extracted with organic solvent such as ethyl acetate, diethyl ether, benzene or the like to remove the anisole and residual of HF.
  • organic solvent such as ethyl acetate, diethyl ether, benzene or the like to remove the anisole and residual of HF.
  • the peptide may be separated from the resin beads by extraction into aqueous acetic acid.
  • the peptide at this stage is not cyclic but is the non-cyclic product without the cyclic disulfide bond between the cysteines at positions 1 and 7 in the molecule.
  • the HF treatment removes all blocking groups from the peptide, except the S-alkylthio blocking groups on the thiol function of cysteine residue at either position 1 or 7.
  • the S-n-alkylthio-L-cysteine residue is stable to the HF cleavage procedure and remains intact throughout the cleavage and extraction procedures.
  • the S-BZ-L-cysteine residue is cleaved by HF to yield a cysteine residue with a free thiol function. Both types of blocking groups have been employed during our synthesis in combination with each other at positions 1 and 7.
  • the peptides obtained after HF cleavage can be one of three types depending upon the blocking groups chosen for the thiol function of the cysteine derivative used during the resin peptide synthesis.
  • the conversion of Types I, II and III peptides to the cyclic disulfide peptides may be performed by diluting with distilled water the aqueous acetic acid solution of the crude peptides from HF cleavage to a final volume of 50 to 200 ml. per gram of resin peptide cleaved.
  • the pH of this solution may be adjusted to 5 to 10 by the addition of ammonium hydroxide solution and the mixture may be stirred in a closed container under a stream of an inert gas such as nitrogen for about 2 to 48 hours.
  • the reaction period can be stopped when the off-gas stream no longer contains n-alkylmercaptan.
  • the pH of the reaction mixture may be lowered to about 3.5 to 5.5 by the addition of glacial acetic acid.
  • Type IV peptides to the cyclic disulfide peptide may be performed by the classical method known to the art in which the peptides are oxidized to join the ring structure to include in the ring the cysteines at positions 1 and 7.
  • the intermediate peptides are of Type I, II, III or IV we may synthesize peptides having amino acid chains corresponding to any known calcitonin except for the substitution of glycine at position 8, and such peptide synthesized as herein set forth may be purified and found to have the same type of biological activity as this known calcitonin. Any calcitonin so synthesized is designated Gly 8-calcitonin. This is in accordance with the IUPAC-IUB method of nomenclature.
  • the crude peptide solutions at pH 5.0 from the above synthesis may be concentrated using an ion-exchange procedure.
  • the concentrate may be purified by a combination of gel-filtration procedures and ion-exchange chromatography methods.
  • the final purified product may be obtained from solution by freeze-drying as a fluffy white solid. The product gives the correct amino acid analysis for the desired peptide.
  • the BHA resin (5g.) with an amine.titer of 0.61 meq./g. was placed in the reactor vessel of a peptide synthesizer marketed by Schwarz-Mann, Inc. of Orangeburg, New York.
  • the resin was treated with 25 ml. of the following solvents filtering after each treatment: Methylene chloride for 2 minutes Chloroform for 2 minutes two times each 10% triethylamine in chloroform for 5 minutes two times each Chloroform for 2 minutes Methylene chloride for 2 minutes three t imes each
  • the L-pr-oline BHA resin was titrated to establish the amine or proline titer. This value was .55 milliequivalents of amine or proline per gram of resin.
  • Cycle 19 2.54 g (0.011 mole) of BOC-L-leucine Cycle 18 -- 4.55 g. (0.011 mole) of BOC- ⁇ -2-chlorocar bonzyloxy-L-lysine Cycle 17 -- 5.14 g. (0.011 mole) of BOC-N(im)-carbo benzyloxy-L-histidine Cycle 16 -- See cycle 19
  • Cycle 12 Same reactants as used in cycle 19
  • Cycle 11 The reactants were the same as in cycle 18 Cycle 10 -- Same reactants as used in cycle 30 Cycle 9 -- Same reactants as used in cycle 19
  • the dried resin peptide (2 g.) and 2 ml. of anisole were placed in a Teflon reaction vessel.
  • the vessel equipped with a Teflon-coated magnet stirrer was placed in a dry ice-acetone bath and 10 ml. of hydrogen fluoride gas was condensed into the vessel. This mixture was stirred at 0 degrees centigrade in an ice bath for 1 hour.
  • the hydrogen fluoride was removed by evaporation at reduced pressure. The residue was triturated with six 10 ml. portions of ethyl acetate.
  • the peptide was extracted from the resin beads with 120 ml. of 0.1 molar aqueous acetic solution.
  • the aqueous acetic acid extract obtained from hydrogen fluoride cleavage was diluted to 0.2 liters by addition of 80 ml. of distilled water.
  • the pH of the solution was adjusted to 7.5 by the addition of concentrated ammonium hydroxide.
  • the solution was stirred in a closed vessel under a stream of nitrogen for 24 hours. At this time no ethyl mercaptan could be detected in the emerging nitrogen stream.
  • the ethyl mercaptan content of the nitrogen stream was measured by passing the stream through a solution of Ellman's reagent [Ellman, G.L., Arch. Biochem. Biophys., 82 , 70-7 (1969)].
  • the pH of the reaction mixture was adjusted to 5.0 by addition of glacial acetic acid.
  • the 0.2 liters of solution from the above synthesis at pH 5.0 was concentrated using a SP-Sephadex C-25 ion-exchange column.
  • the 25 ml. concentrate removed from the column with 0.7 molar sodium chloride solution was desalted and purified by passing through a Sephadex G-25 (fine) gel-filtration column and eluting with 0.03 molar aqueous acetic acid solution.
  • the Gly-8-SCT fraction from this column was adjusted to pH 6.0 by addition of ammonium hydroxide solution.
  • This solution was further purified by ion-exchange chromatography using a Whatman CM52 column eluted with ammonium acetate buffer.
  • the Gly-8-SCT fraction from this column was adjusted to pH 5.0 by addition of glacial acetic acid. This solution was concentrated using a SP-Sephadex C-25 ion-exchange column. The 30 ml. concentrate removed from the column with 0.7 molar sodium chloride solution was desalted with a Sephadex G-25 (fine) gel-filtration column. The purified peptide fraction was collected and freeze-dried. The product was obtained as a fluffy white solid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Nouveaux peptides possédant une activité biologique du même type que les calcitonines connues et qui sont des analogues de substitution des calcitonines naturelles, peptides de résine pouvant être transformés en peptides possédant ladite activité biologique, ainsi que des procédés de production desdits peptides de résine et desdits peptides de calcitonine.
PCT/US1983/000221 1983-02-15 1983-02-15 Glycine-8-calcitonine WO1984003280A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP58501114A JPS60500055A (ja) 1983-02-15 1983-02-15 グリシン−８−カルシトニン
PCT/US1983/000221 WO1984003280A1 (fr) 1983-02-15 1983-02-15 Glycine-8-calcitonine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1983/000221 WO1984003280A1 (fr) 1983-02-15 1983-02-15 Glycine-8-calcitonine

Publications (1)

Publication Number Publication Date
WO1984003280A1 true WO1984003280A1 (fr) 1984-08-30

Family

ID=22174846

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1983/000221 WO1984003280A1 (fr) 1983-02-15 1983-02-15 Glycine-8-calcitonine

Country Status (2)

Country Link
JP (1) JPS60500055A (fr)
WO (1) WO1984003280A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315687A1 (fr) * 1987-05-26 1989-05-17 Rorer Int Overseas (n-alpha-acyl, 8-glycine, des-19-leucine)-calcitonine.

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299037A (en) * 1963-05-02 1967-01-17 Sandoz Ltd Novel polypeptides and intermediates for the preparation therefor
US3299036A (en) * 1963-04-05 1967-01-17 Sandoz Ltd Novel polypeptides and intermediates for the preparation thereof
BE757786A (fr) * 1969-10-22 1971-04-21 Ciba Geigy Nouveaux peptides et procede pour leur preparation
US3798203A (en) * 1969-10-22 1974-03-19 Ciba Geigy Corp Analogues of human thyrocalcitonin modified with corresponding amino acids of salmon thyrocalcitonin and derivatives thereof
US3801561A (en) * 1970-10-29 1974-04-02 Sandoz Ltd Derivatives of salmon thyrocalcitonin
US3849388A (en) * 1968-10-15 1974-11-19 Ciba Geigy Corp Analogues of human thyrocalcitonin
US3891614A (en) * 1972-12-07 1975-06-24 Teikoku Hormone Mfg Co Ltd Solid phase synthesis of calcitonins on benzhydrylamine type resins
US3926938A (en) * 1974-08-12 1975-12-16 Armour Pharma Synthesis of salmon calcitonin
US3929758A (en) * 1974-09-12 1975-12-30 Armour Pharma Cyclization of cysteine-containing peptides
US3988309A (en) * 1973-12-27 1976-10-26 Toyo Jozo Kabushiki Kaisha EEL calcitonin
US4217268A (en) * 1978-07-20 1980-08-12 Hughes John L Synthesis of peptides
US4239680A (en) * 1978-07-24 1980-12-16 Armour And Company Synthesis of biologically active peptides

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299036A (en) * 1963-04-05 1967-01-17 Sandoz Ltd Novel polypeptides and intermediates for the preparation thereof
US3299037A (en) * 1963-05-02 1967-01-17 Sandoz Ltd Novel polypeptides and intermediates for the preparation therefor
US3849388A (en) * 1968-10-15 1974-11-19 Ciba Geigy Corp Analogues of human thyrocalcitonin
BE757786A (fr) * 1969-10-22 1971-04-21 Ciba Geigy Nouveaux peptides et procede pour leur preparation
US3798203A (en) * 1969-10-22 1974-03-19 Ciba Geigy Corp Analogues of human thyrocalcitonin modified with corresponding amino acids of salmon thyrocalcitonin and derivatives thereof
US3801561A (en) * 1970-10-29 1974-04-02 Sandoz Ltd Derivatives of salmon thyrocalcitonin
US3891614A (en) * 1972-12-07 1975-06-24 Teikoku Hormone Mfg Co Ltd Solid phase synthesis of calcitonins on benzhydrylamine type resins
US3988309A (en) * 1973-12-27 1976-10-26 Toyo Jozo Kabushiki Kaisha EEL calcitonin
US3926938A (en) * 1974-08-12 1975-12-16 Armour Pharma Synthesis of salmon calcitonin
US4062815A (en) * 1974-08-12 1977-12-13 Armour Pharmaceutical Company Resin peptides
US3929758A (en) * 1974-09-12 1975-12-30 Armour Pharma Cyclization of cysteine-containing peptides
US4217268A (en) * 1978-07-20 1980-08-12 Hughes John L Synthesis of peptides
US4239680A (en) * 1978-07-24 1980-12-16 Armour And Company Synthesis of biologically active peptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Biochemistry, 79, 1976, NODA, Amino Acid Sequence of Eel Cacitonin, pages 353-359 *
Proceedings of The Second International Symposium, London, July 21-24, 1969, Potts Jr. et al:, Calcitonin: Recent Chemical and Immunological Studies, pages 56-73 *
The Journal of Biological Chemistry, 245, No. 17, September 10, 1970, Brewer, Jr., Isolation and Characterization of Bovine Thyrocalcitonin, pages 4232-4240 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0315687A1 (fr) * 1987-05-26 1989-05-17 Rorer Int Overseas (n-alpha-acyl, 8-glycine, des-19-leucine)-calcitonine.
EP0315687A4 (fr) * 1987-05-26 1990-03-21 Rorer Internat Overseas Inc (n-alpha-acyl, 8-glycine, des-19-leucine)-calcitonine.

Also Published As

Publication number Publication date
JPS60500055A (ja) 1985-01-17
JPS614840B2 (fr) 1986-02-13

Similar Documents

Publication Publication Date Title
US4401593A (en) Glycine - 8 calcitonin
US4217268A (en) Synthesis of peptides
US4597900A (en) Des2 -glycine8 -des22 -calcitonin
US4397780A (en) Leucine22 -calcitonin
US4606856A (en) [Des-1-amino, 8-glycine]calcitonin
US4537716A (en) Des-serine2 or des-glycine2 -leucine22 calcitonin
US4497731A (en) Glycine 8-des-tyrosine 22 calcitonin
US4604238A (en) Analogs of calcitonin
US4495097A (en) Des-serine2 -glycine8 calcitonin
US4414149A (en) Glycine8 -D-arginine24 calcitonin
US4764589A (en) [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin
US4639511A (en) Des-19-leucine-calcitonin analogs
US4632978A (en) 6-serine, des-19-leucine calcitonin
US4528132A (en) [16-Alanine]calcitonin
US4239680A (en) Synthesis of biologically active peptides
US4304692A (en) Synthesis of biologically active peptides
US5001222A (en) Des-17-histidine-calcitonin
US4391747A (en) Des asparagine-3-calcitonin
US4746728A (en) 8-glycine, des-19-leucine-calcitonin
US4764591A (en) Des-19-leucine, 20-glutamine, 21-threonine, 22-tyrosine-calcitonin
US4451395A (en) Des-serine2 -des-tyrosine22 calcitonin
US4764590A (en) Des-19-leucine, 20-glutamine, 21-threonine-calcitonin
US4604237A (en) Des-21-threonine-calcitonin
US4497732A (en) 1A-Endo-glycine-calcitonin
US4604236A (en) Calcitonin analogs

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): JP